TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04113616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232 is an experimental MDM2 inhibitor anti-cancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232 is an experimental MDM2 inhibitor anti-cancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232 is an experimental MDM2 inhibitor anti-cancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232 is an experimental MDM2 inhibitor anti-cancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232 is an experimental MDM2 inhibitor anti-cancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232 is an experimental MDM2 inhibitor anti-cancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine is an anti-cancer chemotherapy drug taken via injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is an anti-cancer chemotherapy drug taken via injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is an anti-cancer chemotherapy drug taken via injection.
Study: NCT02784496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO
Study: NCT01689649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: The patients will receive topiramate tablet twice daily orally up to 16 weeks.
Study: NCT00619918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized 3% saline
Description: 4 ml inhaled q8h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nebulized 0.9% saline
Description: normal saline
Study: NCT06613919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Tuberculosis Treatment
Description: Standard, weight adjusted anti-TB therapy for six months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Tuberculosis Treatment
Description: Standard, weight-adjusted anti-TB therapy for nine months
Study: NCT06615336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Sleep retraining
Description: Intensive Sleep Retraining treatment consisted of 42 sleep onset trials over a 21-hour sleep deprivation period

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation
Description: Total Sleep Deprivation treatment consisted of an equivalent 21-hour sleep deprivation period without sleep onset trials
Study: NCT01350154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: 20 mg in gelatine capsules, oral, three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lactose monohydrate oral in gelatine capsules, 3 times daily
Study: NCT00032032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01573351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir
Study: NCT02302716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2963016
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LANTUS®
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Antihyperglycemic Medication
Description: Administered as per standard-of-care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Antihyperglycemic Medication
Description: Administered as per standard-of-care.
Study: NCT04568577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tape with tension
Description: The elastic bandage will be applied with a voltage increase controlled weekly, for five weeks. Each week, 5% of tension will be added to the application. In the first week the application will be tension-free.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tape without tension
Description: Bandaging applications will be weekly, for five weeks, without tensioning the tape.
Study: NCT04309994

Intervention type: OTHER
Intervention: Myocardial protection system (MPS)
Description: cardioplegia solution, A separate pumpsystem by which Blood cardioplegia with individually composable additives as cardioplegia solution can be used
Study: NCT01573351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-interferon Alfa-2a

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study: NCT03964805

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 20% oxygen
Description: culture excusively at 20% O2 (Day 0 to Day 6)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5% oxygen
Description: culture excusively at 5% O2 (Day 0 to Day 6)
Study: NCT03315221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test product
Description: HMF with added lipids - Intervention group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control product
Description: Commercially available HMF (without lipids) - control group
Study: NCT03964805

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 20 % and 5 % oxygen
Description: culture at 5% from Day 0 to Day 3, then at 20% from Day 3 to Day 6)
Study: NCT01330706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polihexanide
Description: The investigators compared intraoperative antiseptic irrigation using 0.9% saline solution and 0.1% polihexanide.
Study: NCT02022631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternative summary of findings table format
Description: Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current summary of findings table format
Description: Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
Study: NCT02395016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nimotuzumab
Description: nimotuzumab,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo，400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
Study: NCT01998815

Intervention type: PROCEDURE
Intervention: Laparoscopic Roux-en-Y gastric bypass surgery
Study: NCT01070758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide autogel
Description: The dose of Lan-ATG will be calculated according to the surface area of the patient. The dose used in adults is usually 60 mg injection once a month, and we will adapt the patient's dose according to the body surface area and also according to the daily dose of Octreotide used with the pump. The starting dose will be 40 mg/m².
Study: NCT04045795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isatuximab SAR650984 IV
Description: Pharmaceutical form: solution~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isatuximab SAR650984 IV
Description: Pharmaceutical form: solution~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT04309994

Intervention type: OTHER
Intervention: Cardioplexol
Description: cardioplegia solution
Study: NCT04045795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isatuximab SAR650984 SC
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isatuximab SAR650984 SC
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT04276012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention
Description: Psychoeducational intervention, recommendations on life style and diet, medication adherence and changes in pharmacological strategy
Study: NCT04045795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isatuximab SAR650984 SC
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational injector device
Description: Subcutaneous administration
Study: NCT04604158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Elly Mobile Phone Application
Description: The Elly mobile phone application delivers daily audio recording aimed at reducing anxiety, stress, loneliness, and social isolation.
Study: NCT02832167

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT02760355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir 90 mg/Sofosbuvir 400 mg
Description: Oral administration on one fixed dose combination tablet for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Oral administration of body weight-dose adjusted, 200 mg-tablets of ribavirin (1,000 mg in two administration in patients \<75 Kg of body weight, or 1,200 mg in two administrations for those \>75 Kg) for 12 weeks.
Study: NCT01294449

Intervention type: DEVICE
Intervention: MADIT-CRT ICD
Description: Patients that were randomized to the the implantable cardioverter defibrillator (ICD) device for the study.

Intervention type: DEVICE
Intervention: MADIT-CRT CRT-D
Description: Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study.
Study: NCT00218335

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Condition
Description: In the intervention Condition participants were trained to be Health Educators. The intervention focused on HIV risk reduction by teaching knowledge and skills to reduce injection, drug splitting, and sex risk, and by teaching communication skills to conduct outreach to personal risk network members. The intervention consisted of five group-based sessions, one individual session, and one dyad session with a risk network member.
Study: NCT03436836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: Both groups received 8 ml solution for the peribulbar block, Patients of group N was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU)(16) and 4mg of nalbuphine in 1 ml normal saline. Patients of group C was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75 IU) and 1 ml normal saline. Nalbuphine (20mg amp.) was prepared in 0.9% sodium chloride in 5mL syringe.~If the block was inadequate after 10 minutes, a 2-4 ml supplementation of local anesthetics was given by the same technique and the patient was excluded from the study.~After adequate analgesia (loss of sensation to touch by a small cotton wool) and akinesia, the surgeon was allowed to start the surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine, bupivacaine, hyaluronidase , saline
Description: lidocaine, 0.5% bupivacaine, 1 ml hyaluronidase (75 IU) and 1 ml saline (total 8 ml).
Study: NCT00218335

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Condition
Description: The control condition focused on injection drug-use related topics (e.g. HIV testing, Hepatitis C and drug overdose). The sessions were educational and did not include skills training. The control condition consisted of five group-based sessions.
Study: NCT01677650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Methadone IV Pre-Induction of Anesthesia 0.15 to 0.5 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Methadone IV Pre-Induction of Anesthesia 0.15 to 0.5 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Methadone IV Pre-Induction of Anesthesia 0.15 to 0.5 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Methadone IV Pre-Induction of Anesthesia 0.15 to 0.5 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Methadone IV Pre-Induction of Anesthesia 0.15 to 0.5 mg/kg
Study: NCT03885336

Intervention type: OTHER
Intervention: No Interventions
Description: There are no interventions in this study. Participants are observed.
Study: NCT02566096

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: transversus abdominis-plane block with local anesthetic 20 ml of bupivacaine 0.5% + 10 mg morphine
Description: compare the analgesic efficacy of transversus abdominis-plane block with bupivicaine with morphine in patients undergoing major abdominal cancer surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transversus abdominis-plane block with local anesthetic 20 ml of bupivacaine 0.5% + 10 mg morphine
Description: compare the analgesic efficacy of transversus abdominis-plane block with bupivicaine with morphine in patients undergoing major abdominal cancer surgery.
Study: NCT03904836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin
Description: 5 milligrams per kilogram intravenous for one dose
Study: NCT00652002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: formoterol
Study: NCT02687789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device: WO3191
Description: application of vaginal suppository WO3191: 2 days per week (with a treatment-free interval of three days or two days, respectively; e.g. Monday and Friday)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device: Vagisan® Lactic Acid
Description: application of Vagisan® Lactic Acid: 2 days per week (with a treatment-free interval of three days or two days, respectively; e.g. Monday and Friday)
Study: NCT04281524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL312
Description: CSL312 administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL312
Description: CSL312 administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL312
Description: CSL312 administered as an IV infusion
Study: NCT03436836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine, bupivacaine , hyaluronidase
Description: 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU)
Study: NCT01570920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical training
Description: walking many times a week
Study: NCT01848197

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT05533723

Intervention type: PROCEDURE
Intervention: Endoscopic epidural neuroplasty
Description: EEN catheter, iDolphine S2 (Meta Biomed Co., Ltd, Osong, Korea) was placed in the epidural space through sacral hiatus. EEN was done on the target segments.~During EEN, normal saline was infused into epidural space under epiduroscopic vision. Dexamethasone (5 mg), 0.3% mepivacaine 10 mL, and hyaluronidase (3000 IU) were injected through catheter at the target segments. Holmium-Yag laser was used to cut epidural fibrous bands and for coagulation of epidural bleeding.

Intervention type: PROCEDURE
Intervention: Percutaneous epidural neuroplasty (PEN)
Description: PEN catheter, EDEN-CC (JMT, Yangju, Korea) was placed in the epidural space and neural foramen . PEN was done on the target segments. Dexamethasone (5 mg), 0.3% mepivacaine 10 ml, and hyaluronidase (3000 IU) were injected through the PEN catheter.
Study: NCT04281524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL312
Description: CSL312 administered as an IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution of 70% 0.9% saline / 30% CSL312 diluent
Study: NCT04117945

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given PO
Study: NCT06359340

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial treatment
Description: Participants randomly assigned to one of four psychosocial treatment conditions including cognitive behavioral therapy and a certified recovery specialist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial treatment
Description: Participants randomly assigned to one of four psychosocial treatment conditions including cognitive behavioral therapy and a certified recovery specialist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial treatment
Description: Participants randomly assigned to one of four psychosocial treatment conditions including cognitive behavioral therapy and a certified recovery specialist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial treatment
Description: Participants randomly assigned to one of four psychosocial treatment conditions including cognitive behavioral therapy and a certified recovery specialist.
Study: NCT03769532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (IMP): 200mg i.v. (fixed dose), every 3 weeks (Q3W), 8 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine (SOC): 75 mg/m2 s.c., day 1-7 every 4 weeks (Q4W), 6 cycles
Study: NCT03928236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Limited Intraoperative Benzodiazepine
Description: policy for limited use of intraoperative benzodiazepine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liberal Intraoperative Benzodiazepine
Description: policy for liberal use of intraoperative benzodiazepine
Study: NCT03865225

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback
Description: 9 x 10 minutes biofeedback sessions over period of three days

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-Biofeedback
Description: 9 x 10 minutes sham-biofeedback sessions over period of three days
Study: NCT00458159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-11006
Description: Doses: 10mg, 15mg, 25mg, 35mg, \& 50mg, taken once daily, orally.
Study: NCT03853096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: Cefazolin 100mg/mL, 3mL in three locations will be administered around a surgical incision on the anterior shoulder in a standard deltopectoral approach interval. This will be a one time administration. Administration and route will be subcutaneous.
Study: NCT01917084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive range of motion (ROM) exercise
Description: After their Norwood surgery, stable subjects will undergo passive ROM exercise therapy for up to 21 consecutive days or until hospital discharge, whichever comes first. Subjects will have completed the study after their anthropometric measurements are collected at 3 months of age
Study: NCT01226524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bu Zhong Yi Qi Tang, Zhi Xue Tang, Chuan xin lian kang yan pian mod, Tian Wang Bu xin Dan
Description: A traditional Chinese Medicine (TCM) therapist will diagnose and prescribe the herbal remedies according to TCM principles from one of four formulations or any combination of the four formulation
Study: NCT03417739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVD-523
Description: ERK1 and ERK2 inhibitor
Study: NCT02928458

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omnipaque

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MD-Gastroview